SLC5A2 and Schnyder corneal dystrophy: Several cardiorenal protective actions of SGLT2 inhibitors result in hemodynamic improvement, reverse remodeling of the failing heart, decreased sympathetic hyperactivity, correction of electrolyte disturbances, restoration of anemia and iron metabolism, antioxidative and antifibrotic effects, which may all contribute to the prevention of SCD and/or VAs [107].